4Tissue

Executive Summary

4Tissue is a Belgian biotechnology company spun out from a university in 2016, specializing in minimally invasive injectable hydrogel solutions for tissue reconstruction and regeneration. Its lead application targets breast reconstruction following mastectomy, aiming to improve cell survival and promote natural tissue formation as an alternative to traditional implants or flap surgeries. The company's hydrogel technology is designed to be delivered via injection, reducing surgical trauma and enabling scaffold-free tissue regeneration. While still in early development stages, 4Tissue addresses a significant unmet need in reconstructive surgery, particularly for patients seeking less invasive options with potentially better aesthetic outcomes. The approach could also be extendable to other tissue types, broadening its market potential. However, the company remains pre-revenue and likely at preclinical or early clinical phase, with no disclosed funding rounds or valuation.

Upcoming Catalysts (preview)

• Q3 2026Advancement of lead breast reconstruction program into first-in-human clinical trial30% success
• Q4 2026Series A financing round closure to support clinical development60% success
• Q2 2027Strategic partnership with a medtech or pharmaceutical company for co-development or licensing40% success